Paper Details

  1. Home
  2. Paper Details

The efficacy and immunological effects of upadacitinib in the treatment of moderate-to-severe Chinese atopic dermatitis patients.

Author: HeTing, LiLu, LiYan, LiuTingyu, MaoRaymond, ShenChen, TaoJuan, WangYifei, WuNaming, YangLiu, YuGuoqun

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Upadacitinib, a JAK1 inhibitor, effectively improved clinical scores in 25 Chinese patients with moderate-to-severe atopic dermatitis (AD) in a real-world study. It significantly reduced blood eosinophils and neutrophils and lowered levels of Th1, Th2, and Th17/22-type cytokines. Notably, upadacitinib reduced both IL-22+CD4+ T cells and serum IL-22 levels, including in patients with recalcitrant AD.
Paper Details　
Original Abstract of the Article :
Upadacitinib has received approval for the treatment of atopic dermatitis (AD) with favorable response in clinical trials. However, real-world research on its efficacy remains relatively limited. To bridge this gap, we conducted a prospective cohort study involving 25 Chinese patients with moderate-...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.intimp.2023.111193

データ提供：米国国立医学図書館（NLM）

Upadacitinib: A New Hope for Chinese Atopic Dermatitis Patients

Atopic dermatitis, like a desert wind, can leave skin feeling dry, itchy, and inflamed. This research focuses on the efficacy and immunological effects of upadacitinib, a new treatment for atopic dermatitis (AD) in Chinese patients. The study, a prospective cohort study, evaluated the real-world efficacy of upadacitinib in 25 patients with moderate-to-severe AD.

The findings revealed that upadacitinib significantly improved clinical scores in patients with AD. The researchers also observed a significant reduction in peripheral blood eosinophils and a decrease in neutrophil count, suggesting a positive impact on the immune system. Furthermore, the study found that upadacitinib treatment resulted in a decrease in Th1, Th2, and Th17/22-type cytokines, as well as other inflammatory factors.

Effective Treatment and Immunological Impact

This study provides valuable insights into the real-world effectiveness and immunological impacts of upadacitinib treatment for AD in Chinese patients. The significant improvements in clinical scores and the observed reduction in inflammatory markers suggest that upadacitinib could offer a promising treatment option for individuals with AD.

A New Frontier in Atopic Dermatitis Treatment

This research, with its focus on the real-world application of upadacitinib, expands our understanding of this medication's potential benefits. The positive results and the observed immunological impact provide compelling evidence for further exploration and clinical utilization of upadacitinib in treating AD.

Dr. Camel's Conclusion

Just as a desert plant adapts to survive harsh conditions, our bodies strive to maintain balance. This research shows how upadacitinib can help restore that balance in individuals with atopic dermatitis, offering a potential oasis of relief from the discomfort and inflammation of this skin condition.

Date :
  1. Date Completed 2023-11-20
  2. Date Revised 2023-11-20
Further Info :

Pubmed ID

37939514

DOI: Digital Object Identifier

10.1016/j.intimp.2023.111193

Related Literature

Article Analysis
・Effects of upadacitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.